Hypoxia, HIF1α and estrogen receptor;Hypoxie, HIF1α et récepteur aux œstrogènes

Bulletin du Cancer

Volumn 91, Issue 9, 2004, Pages 677-683

  Massaad Massade, Liliane ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Estrogen receptor; Hypoxia; Signalisation pathways; Treatment

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHOTREXATE; RALOXIFENE; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; TIRAPAZAMINE; DNA BINDING PROTEIN; ERYTHROPOIETIN; ESTRADIOL; HEMOGLOBIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VASCULOTROPIN A; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

AMINO ACID SEQUENCE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG RESPONSE; EXPERIMENT; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HISTOCHEMISTRY; HUMAN; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VASCULARIZATION; BREAST TUMOR; CELL HYPOXIA; DRUG RESISTANCE; FEMALE; METABOLISM; MORTALITY; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL HYPOXIA; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ERYTHROPOIETIN; ESTRADIOL; FEMALE; GENE THERAPY; HEMOGLOBINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR PROTEINS; PROGNOSIS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 6044242248     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Cancer CDOSL. Rapport remis au ministre de la Santé par la Commission d'orientation sur le cancer. Ministère de la Santé 2003.
2. Chaplain GCM, Buemi A, Gros-Claude P, Arveux P, Daures JP, et al. Estimation de l'incidence du cancer du sein en France en 1995. Le Sein 1999 ; 9 : 126-30.
3. Begg L, Kuller LH, Gutai JP, Caggiula AG, Wolmark N, Watson CG. Endogenous sex hormone levels and breast cancer risk. Genet Epidemiol 1987 ; 4 : 233-47.
4. Chalbos D, Vignon F, Keydar I, Rochefort H. Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J Clin Endocrinol Metab 1982 ; 55 : 276-83.
5. Dickson RB, McManaway ME, Lippman ME. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 1986 ; 232 : 1540-3.
6. El-Tanani MK, Green CD. Interaction between estradiol and growth factors in the regulation of specific gene expression in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 1997 ; 60 : 269-76.
7. Vignon F, Prebois C, Rochefort H, Dreicer R, Wilding G. Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 1992 ; 84 : 38-42.
8. Nardulli AM, Katzenellenbogen BS. Progesterone receptor regulation in T47D human breast cancer cells : analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. Endocrinology 1988 ; 122 : 1532-40.
9. Klijn JG, Berns EM, Foekens JA. Prognostic factors and response to therapy in breast cancer. Cancer Surv 1993 ; 18 : 165-98.
10. Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996 ; 73 : 1545-51.
11. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001 ; 28 : 36-41.
12. 2 homeostasis by hypoxia-inducible factor 1. Expression of hypoxia-inducible factor 1 : mechanisms and consequences. Annu Rev Cell Dev Biol 1999 ; 15 : 551-78.
13. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998 ; 12 : 149-62.
14. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogentsis,. J Natl Cancer Inst 2001 ; 93 : 309-14.
15. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-lalpha independently predict prognosis in patients with lymph node negarive breast carcinoma. Cancer 2003 ; 97 : 1573-81.
16. Nomenclature. TASfBaMRPsCo. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999 ; 97 : 161-3.
17. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily : the second decade. Cell 1995 ; 83 : 835-9.
18. Klein-Hitpass L, Ryffel GU, Heitlinger E, Cato AC. A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res 1988 ; 16 : 647-63.
19. Martinez E, Givel F, Wahli W. The estrogen-responsive element as an inducible enhancer : DNA sequence requirements and conversion to a glucocorticoid-responsive element. EMBO J 1987 ; 6 : 3719-27.
20. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell 1987 ; 51 : 941-51.
21. Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988 ; 55 : 145-56.
22. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 1998 ; 95 : 993-8.
23. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000 ; 275 : 25733-41.
24. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999 ; 399 : 271-5.
25. Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex : implications for VHL tumor suppressor function. Science 1999 ; 284 : 455-61.
26. 2 sensing. Science 2001 ; 292 : 464-8.
27. 2-regulated prolyl hydroxylation. Science 2001 ; 292 : 468-72.
28. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001 ; 20 : 5197-206.
29. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003 ; 20 : 237-50.
30. Vandenbunder B. Hypoxie et tumeurs : le facteur de transcription HIF-1 favorise-t-il la croissance ou l'asphyxie des tumeurs? Bull Cancer 1998 ; 85 : 843-5.
31. 2 homeostasis. Curr Opin Genet Dev 1998 ; 8 : 588-94.
32. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphotylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999 ; 274 : 32631-7.
33. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002 ; 8 : 1831-7.
34. Helczynska K, Kronblad A, Jogi A, Nilsson E, Beckman S, Landberg G, et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 2003 ; 63 : 1441-4.
35. Cayre A, Rossignol F, Clottes E, Penault-Llorca F. aHIF but not HIF-1alpha transcript is a poor prognostic marker in human breast cancer. Breast Cancer Res 2003 ; 5 : 223-30.
36. Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, Djonov V. Hypoxia-inducible factor 1 alpha in high-risk breast cancer : an independent prognostic parameter? Breast Cancer Res 2004 ; 6 : 191-8.
37. Hockel M, Vaupel P. Tumor hypoxia : definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001 ; 93 : 266-76.
38. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997 ; 147 : 541-50.
39. Bachtiaty B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner J A, et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003 ; 9 : 2234-40.
40. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha : a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001 ; 61 : 2911-6.
41. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002 ; 8 : 2595-604.
42. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, et al. Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001 ; 61 : 1830-2.
43. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, et al. Molecular targeting therapy of cancer : drug resistance, apoptosis and survival signal. Cancer Sci 2003 ; 94 : 15-21.
44. Ojugo AS, McSheehy PM, Stubbs M, Alder G, Bashford CL, Maxwell RJ, et al. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br J Cancer 1998 ; 77 : 873-9.
45. Griffiths L, Dachs GU, Bicknell R, et al. The influence of oxygen tension and pH on the expression of platelet derived endothelial cell growth factor/thymidine phosphorylase in human breast tumour cells grown in vitro and in vivo. Cancer Res 1997 ; 57 : 570-2.
46. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994 ; 13 : 139-68.
47. Kurebayashi J. Endocrine-resistant breast cancer : underlying mechanisms and strategies for overcoming resistance. Breast Cancer 2003 ; 10 : 112-9.
48. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001 ; 61 : 5407-14.
49. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells : a complex interplay between estrogen receptors alpha and beta. Cancer Res 2002 ; 62 : 4977-84.
50. Coradini D, Pellizzaro C, Spetanza A, Daidone MG. Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens. Cell Mol Life Sci 2004 ; 61 : 76-82.
51. Kurebayashi J, Otsuki T, Moriya T, Sonoo H. Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 2001 ; 92 : 1093-101.
52. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001 ; 28 : 49-53.
53. Leyland-Jones B, O'Shaughnessy JA. Erythropoietin as a critical component of breast cancer therapy : survival, synergistic, and cognitive applications. Semin Oncol 2003 ; 30 : 174-84.
54. Leyland-Jones B, Best Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003 ; 4 : 459-60.
55. Browet V. Erythropoietin may impair, not improve, cancer survival. Nature Med 2003 ; 9 : 1439.
56. Brower V. Epoetin for cancer patients : a boon or a danger? J Natl Cancer Inst 2003 ; 95 : 1820-1.
57. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schafer B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy : randomised, double-blind, placebo-controlled trial. Lancet 2003 ; 362 : 1255-60.
58. Koukourakis MI. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC) : a new concept in radiotherapy and encouraging results in breast cancer. Semin Oncol 2002 ; 29 : 42-6.
59. Gandara DR, Lara PN, Goldberg Z, Le QT, Mack PC, Lau DH, et al. Tirapazamine : prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 2002 ; 29 : 102-9.
60. Ramji S, Lee C, Inaba T, Patterson AV, Riddick DS. Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines. Cancer Res 2003 ; 63 : 6914-9.
61. L'Allemain G. Le facteur de l'hypoxie HIF : future cible pharmacologique. Bull Cancer 2002 ; 89 : 257-60.
62. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 2001 ; 8 : 638-45.
63. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003 ; 278 : 14013-9.
64. Burke B, Tang N, Cotke KP, Tazzyman D, Ameri K, Wells M, Lewis CE. Expression of HIF-1alpha by human macrophages : implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002 ; 196 : 204-12.